Bio View Financials
| BIOV Stock | ILS 25.30 0.90 3.44% |
Bio |
Understanding current and past Bio View Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Bio View's financial statements are interrelated, with each one affecting the others. For example, an increase in Bio View's assets may result in an increase in income on the income statement.
Please note, the presentation of Bio View's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bio View's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Bio View's management manipulating its earnings.
Bio View Stock Summary
Bio View competes with Migdal Insurance, Storage Drop, One Software, Bio Meat, and Israel China. BioView Ltd. develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company was founded in 2000 and is headquartered in Rehovot, Israel. BIO VIEW is traded on Tel Aviv Stock Exchange in Israel.| Foreign Associate | USA |
| Instrument | Israel Stock View All |
| Exchange | Tel Aviv Stock Exchange |
| ISIN | IL0010960495 |
| Business Address | 3 Pekeris Street, |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.bioview.com |
| Phone | 972 73 227 1025 |
| Currency | ILS - Israeli Shekel |
You should never invest in Bio View without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Bio Stock, because this is throwing your money away. Analyzing the key information contained in Bio View's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Bio View Key Financial Ratios
Bio View's financial ratios allow both analysts and investors to convert raw data from Bio View's financial statements into concise, actionable information that can be used to evaluate the performance of Bio View over time and compare it to other companies across industries.| Return On Equity | 0.0399 | |||
| Return On Asset | 0.0091 | |||
| Number Of Employees | 35 | |||
| Beta | 0.53 | |||
| Z Score | 12.0 |
Bio Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bio View's current stock value. Our valuation model uses many indicators to compare Bio View value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bio View competition to find correlations between indicators driving Bio View's intrinsic value. More Info.Bio View is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.23 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Bio View is roughly 4.38 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Bio View by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Bio View's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Bio View Systematic Risk
Bio View's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Bio View volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Bio View correlated with the market. If Beta is less than 0 Bio View generally moves in the opposite direction as compared to the market. If Bio View Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Bio View is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Bio View is generally in the same direction as the market. If Beta > 1 Bio View moves generally in the same direction as, but more than the movement of the benchmark.
Bio View November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Bio View help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bio View. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bio View based on widely used predictive technical indicators. In general, we focus on analyzing Bio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bio View's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.08 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 22.33 | |||
| Value At Risk | (5.24) | |||
| Potential Upside | 7.92 |
Complementary Tools for Bio Stock analysis
When running Bio View's price analysis, check to measure Bio View's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio View is operating at the current time. Most of Bio View's value examination focuses on studying past and present price action to predict the probability of Bio View's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio View's price. Additionally, you may evaluate how the addition of Bio View to your portfolios can decrease your overall portfolio volatility.
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |